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Abstract
Cerebral small vessel disease (SVD) is a major health burden, yet the pathophysiology remains poorly understood with no
effective treatment. Since much of SVD develops silently and insidiously, non-invasive neuroimaging such as MRI is funda-
mental to detecting and understanding SVD in humans. Several relevant SVD rodent models are established for which MRI can
monitor in vivo changes over time prior to histological examination. Here, we critically review the MRI methods pertaining to
salient rodent models and evaluate synergies with human SVD MRI methods. We found few relevant publications, but argue
there is considerable scope for greater use of MRI in rodent models, and opportunities for harmonisation of the rodent-human
methods to increase the translational potential of models to understand SVD in humans. We summarise current MR techniques
used in SVD research, provide recommendations and examples and highlight practicalities for use of MRI SVD imaging
protocols in pre-selected, relevant rodent models.
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Introduction
Cerebral small vessel disease (SVD) is estimated to cause 20–
25% of strokes globally and 45–65% of dementias [1, 2].
Magnetic resonance imaging (MRI) is used extensively in
clinics and research to identify SVD-associated lesions and
imaging biomarkers. Key SVD-related features, image acqui-
sition and quantification methods are summarised in recent
position papers [3, 4].
The core diagnostic SVD protocol includes the following:
T1-weighted (T1-w), to provide detailed anatomical images,
identify brain atrophy and differentiate grey/white matter; T2-
weighted (T2-w), to distinguish lacunes from dilated
perivascular spaces (PVS) or white matter hyperintensities
(WMH); fluid-attenuated inversion recovery (FLAIR), to
identify WMH, lacunes and established infarcts; diffusion-
weighted imaging (DWI), to detect recent small infarcts due
to high sensitivity to acute ischaemia [5]; and blood sensitive
(gradient echo (GRE)/T2*-w or susceptibility-weighted imag-
ing), to identify cerebral microbleeds, superficial siderosis and
mineral deposition [3].
Advanced MRI techniques aid research into SVD
pathogenesis [6] including DTI, to assess white matter
integrity, and methods, to assess microvascular function,
including cerebrovascular reactivity (CVR), intracranial
vascular and cerebrospinal fluid (CSF) pulsatility, cere-
bral blood flow (CBF) and blood–brain barrier (BBB)
integrity. Dynamic and static CBF is important in
assessing cerebrovascular health [7]. Dynamic blood
flow responsiveness is commonly assessed with blood
oxygenation level–dependent (BOLD) [8]. Resting CBF
can be measured by dynamic susceptibility contrast
(DSC), arterial spin labelling (ASL) and phase contrast
MRI (PC-MRI). Dynamic contrast-enhanced (DCE) MRI
using intravenous injection of gadolinium (Gd) contrast
[9] shows increased BBB permeability in SVD [4,
10–12]. Magnetic resonance spectroscopy (MRS) detects
neuro-metabolite changes, including evidence of axonal
loss/disruption [13, 14].
Various rodent models reflect different putative SVD
mechanisms and some features of human disease
[15–19]. Hypertension models replicate elements of
microvessel remodelling from some sporadic human
SVD [20], including venous collagenosis [21], but hy-
pertension is only one risk factor. The spontaneously
hypertensive stroke prone rat (SHRSP) has endothelial
dysfunction, microglial, white matter and BBB abnormalities
prior to hypertension and sporadic SVD features when older
[18]. Bilateral carotid arterymicrocoils to inducemild stenosis
(BCAS) leads to some SVD characteristics [22, 23] but may
work through altering carotid elasticity and arterial pulsatility.
There are also several monogenic SVD and knockout models
[19, 24, 25].
There are some inherent limitations to the translational po-
tential of animal models [15, 16, 18]. Anatomically,
white:grey matter ratios and brain sizes differ markedly
(Fig. 1) [15, 16]; arterial anatomy [26, 27], density,
spacing and positioning of penetrating arterioles and
draining venules also vary [28]. In stroke models,
assessing rodent neurological deficits is challenging
when symptoms are mild and recovery may be rapid
[29]. Anaesthetics, necessary for many types of study,
can affect cerebral haemodynamics and CSF transport
[30] and may provide neuroprotective or adversive ef-
fects that could alter the tissue changes [31, 32]. Rodent
respiratory and heart rates are higher, restricting options
for physiological measurements and pulse gating re-
quired for some MR sequences at comparable temporal
resolution to humans.
Despite the anatomical and physiological differences
from humans, rodent SVD models are however key for
investigating pathological processes and time trajecto-
ries of disease evolution and developing and testing
novel therapies [33]. Preclinical MRI facilitates inde-
pendent validation with contemporaneous histology or
other imaging techniques and improves clinical transla-
tion and exploration of physiological processes, e.g.
fluid flow through the glymphatic system [34–36],
glymphatic system changes during sleep [37] and ef-
fects of risk factors, including hypertension and diabe-
tes, on tissue damage and microvascular fluid dynamics
[38, 39].
As part of efforts to improve the translational value
of preclinical models to human SVD, particularly
through the use of MRI, we reviewed the literature to
identify studies which had adapted clinical MRI
methods to preclinical MRI, or vice versa. Our intention
is not to review preclinical SVD rodent models but
rather to evaluate synergies, strengths and limitations
between human and rodent MRI to optimise the trans-
lational potential of MRI for non-invasive longitudinal
assessment of disease development and progression in
SVD.
Methods
Systematic Review
We reviewed the literature to extract information on ap-
proaches to improving comparability or complementarity of
brain MRI techniques between studies in rodents and humans.
The systematic literature search was conducted on Medline
and Embase from 1946 until April 2020 through Ovid.
Exploded headings and search terms relating to SVD were
combined with terms for MRI and relevant advanced MR
Transl. Stroke Res.
techniques. We also combined these results with a compre-
hensive search strategy for rodents based on Hooijmans
et al.’s filter [40] and terms associated with translational
research (e.g. translat*, retranslat*) prior to limiting to papers
relating to humans. Finally, we removed duplicates. For the
full search strategy, see the Supplementary Material.
Fig. 1 Approximate total intracranial volume (TIV) volume (ml) and greymatter:white matter:CSF ratio in healthy (young) animals shown relative to the
human brain based on publicly available templates
Transl. Stroke Res.
We also manually checked reference lists in reviews and
original papers for additional relevant references. Other papers
were identified from the authors’ libraries. We inspected all
identified papers to ascertain whether they satisfied the eligi-
bility criteria. We included papers that provided information
on MRI methods designed to be used in humans and those
designed for use in rodent models but that aimed to capture
SVD features, including static [41] and dynamic biomarkers
(e.g. vascular reactivity and BBB dynamics), which use sim-
ilar sequences in rodents and humans including practical guid-
ance. We excluded studies published solely as conference
abstracts due to providing insufficient detail.
One author (MSS) extracted summary data for each paper
including the type of publication, diseases covered, imaging
techniques employed and a short summary of the focus. Other
authors resolved uncertainties. We sought to provide an over-
view of all published strategies for comparable human-rodent
MR imaging protocols, practicalities and advice on specific
sequence(s) including structural, post-mortem and dynamic
vascular function assessments including CVR and DCE.
Results
The search identified 305 unique publications of which we
excluded 260 as irrelevant based on the title, mainly due to
being in an unrelated population, case reports or modality (e.g.
positron emission tomography (PET), computed tomography
(CT)) (Fig. 2). On full-text review of the remaining 45, a
further 30 were excluded, mainly due to the following: no
MRI (12), translation of other biomarkers for drug develop-
ment (five), clinical or preclinical studies only (six), confer-
ence abstracts (six) and one book.
Of the 15 relevant papers that addressed any aspect of
rodent-human MRI, seven were narrative reviews [42–48],
one was an editorial [49] and seven were original research
[22, 50–55] (Table 1). Of these, six focused on AD (four
reviews [42–45], one editorial [49] and one original paper
[52]), one review [47] on stroke, two original papers on
Huntington’s disease [51, 54], one original paper each on
ageing [50] and hypertension [55], two original papers [22,
53] and one review on SVD [48] and one review briefly
summarised functional MRI (fMRI) applications in several
diseases [46], including stroke and neurodegeneration.
All studies were cross-sectional [22, 50, 52–55] with the
exception of the preclinical component of [51] which was
longitudinal.
We found no protocol with guidance on designing longitu-
dinal MRI studies in rodents to mirror typical MRI research to
examine disease development in human cohorts. One rodent
protocol used DTI, T2w, T1w and T2*w but not FLAIR [22].
No studies addressed image analysis issues that are commonly
encountered in human studies, such as image registration and
lesion tracking over time, or combining data from several
different sequences from the same anatomical regions or le-
sions at one time point. We did find a few studies where
assessment tools developed to assess SVD features in humans,
such as the Fazekas scale for WMH [56], Brain Observer
MicroBleed Scale (BOMBS) for cerebral microbleeds [57]
and several image analysis methods such as segmentation
and voxel-based morphometry, have been adapted for use in
animal models [22, 54].We also found one example of a novel
imaging approach developed to assess perivascular space fluid
uptake in rodents that had been translated to human use [53].
There were few studies where MRI had been used to assess
response to treatment in rodents [42, 43]. The review papers
highlighted several complementary methods including mi-
croscopy [45] and functional [43, 45, 46] and in vivo and
ex vivo structural MR imaging [22, 42, 44, 45, 50]
(Table 1). However, these methods were only rarely used
Fig. 2 PRISMA flow diagram of
the literature search
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together in the same study for validation [49]. Lastly, several
technology [44] or transferability [45, 46] limitations for clin-
ical to preclinical and vice versa were highlighted, including
the need for further validation and methodological advance-
ments to provide scans with higher sensitivity and specificity.
There was no detailed overview of a range of MR imaging
techniques applied in rodents in disease- or lesion-specific
contexts to mirror those developed to study human SVD [3].
Proposed Approaches to Improve
the Potential of Rodent-Human Translational
MRI
Structural MRI in Rodents and Humans
Human SVD features are present in many models [15, 17, 18,
50]. Certain features are less commonly reported; however,
PVS were only recently identified clinically and appear on
histology in pericyte-deficient mice [19]. Therefore, optimised
parameters enhancing visibility of disease-related features
should be used and standardised where possible (https://
harness-neuroimaging.org/) [4].
Translational SVD research must account for practical dif-
ferences. Rodent imaging needs ultra-high magnetic field
strengths (i.e. ≥ 7 T) as a necessary and common means of
increasing signal-to-noise ratio due to smaller spatial resolu-
tion. In human imaging, acquisitions can be accelerated via
several techniques, including compressed sensing and parallel
imaging [59, 60], thereby reducing motion artefact while
allowing incredibly detailed 3D acquisitions in clinically ac-
ceptable times; however, such acceleration methods are often
less readily available on preclinical platforms. Variations in
preclinical pulse sequences may affect comparability of
contrast-to-noise ratio (CNR) and image interpretation
(Fig. 3). Applying clinical imaging protocols may better inte-
grate translational work, track disease progression/assessment
(Fig. 4) and improve cross-model methodological
translatability.
Possible exemplar sequences, based on ones found to be
reliable and informative at the authors’ sites, are listed in
Table 2. Options include 2D or 3D sequences, but while 3D
are desirable, they take longer than 2D, so 2D may be prefer-
able in some situations.
Validation of pathogenic mechanisms, tissue changes and
evolution, complemented by invasive measurements, e.g. 2-
photon [38] and post-mortem microscopy, are main reasons
for using preclinical models. Preclinical imaging allows
longer/more regular scanning and examination using multiple
modalities. Advanced structural scans provide useful addi-
tional metrics, e.g. DTI for white matter tract integrity/visual-
isation, and network connectivity assessment, which may help
explore cognitive/functional deficits.T
ab
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Anatomical factors that may affect the translational poten-
tial include appropriate metrics/methods to control for relative
brain size/tissue ratios and the effects of interventions to in-
crease SVD burden. Clinical SVD features typically increase
with age; hence, while using naturally aged rodents [61] may
be more challenging and costly, they may reveal more obvi-
ous features plus be relevant to longitudinal studies and valu-
able for preclinical drug testing.
Fig. 4 Illustrations of commonly used structural imaging contrasts in human, rat and mouse models (Human 3 T: MS/JMW, Rat: HL, Mouse: AM). 7 T,
9.4 T and even higher field strengths are commonly used in rodent imaging
Fig. 3 Examples of the appearance of SVD features in human, from left to right: recent small subcortical (i.e. acute lacunar) infarct (DWI), WMH
(FLAIR), lacune (FLAIR) and enlarged perivascular spaces (T2-w) indicated by yellow arrows
Transl. Stroke Res.
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A Greater Role for Post-Mortem MRI in Humans
and Rodents
Post-mortem MR (PM-MRI) shows the neuropathology and
macroscopic tissue damage underlying MRI features [62, 63].
Long scans are much more feasible PM yielding better image
quality with corresponding benefits to signal-to-noise ratio
(SNR), spatial resolution and reduced partial volume, thereby
enabling precise MR-histology comparisons. Formalin-
perfusion fixation improves contrast-to-noise (CNR) for MR
microscopy; while SVD lesions remain conspicuous [51,
64–66], prolonged fixation may also induce signal artefacts
obscuring lesions [67] and discriminating between pre- and
post-mortem damage on MRI may be more challenging (e.g.
small parenchymal haemorrhage versus post-mortem intra-
vascular thrombus) [68]. While perfusion fixation is the gold
standard for preclinical models, immersion is often preferred
in humans for practical reasons. Optimal perfusion fixation is
also important to avoid post-mortem intravascular thrombus
mimicking pre-mortem intravascular thrombus for example
[69]. The time of sacrifice and fixation method must therefore
be carefully considered. There are validated protocols relating
pre-mortem and PM human MR-visible SVD lesions to his-
tology [62, 70, 71]. While some features may be less evident
at PM, PM-MRI is well-suited to automated analysis and is
underused in SVD research.
Few papers directly compare PM-MRI to histology
[72–75]. Non-quantitative analyses, assessing overall distribu-
tion and size [76], risk missing heterogeneous WMH features,
including pathological variation [77]. There are limited data
on lesion development in rodents during normal ageing; opti-
misation studies could explore histological-MRI correlates
across the lifespan. Close scrutiny of structural and quantita-
tive images by experts in human MRI may identify lesion
development stages on PM-MRI. Ex vivo DTI gives data for
large areas of tissue and thus can complement and guide the
‘spot sampling’ approaches typical of histological assessment
of white matter integrity [78, 79].
Cerebral microinfarcts (CMIs), small ischaemic lesions
encompassing neuronal loss, gliosis and cavitation [80], can
appear acutely on diffusion imaging. However, size and signal
transience may lead to underestimation of frequency and in-
volvement [71, 81]. PM-MRI allows direct histopathological
validation of specific imaging markers [82] including in ro-
dent models. Studies comparing ex vivoMRwith histology of
CMIs are sparse. More studies would help determine the role
of CMIs in SVD and neurodegeneration and help improve the
spatial resolution.
Cerebral microbleeds (CMBs), small chronic haemorrhages,
appear hypointense on T2*-w/SWI [3, 83] and are not visible
on other sequences. CMBs remain visible post-mortem,
mirroring histopathology and pre-mortem appearances [84,
85]. Underlying pathological features occurring within CMBs
include acute/old (macro)haemorrhages and residual
haemosiderin [86]. Paramagnetic properties cause blooming,
lesion size overestimation and potential false positives on
MRI [87], reinforcing the value of targeted histology alongside
MRI measurements. Haemosiderin deposition is detected [19,
88] in amyloid pathologymice, in whomT2*-wCMBs are also
reported to correlate with histology [89, 90]. Susceptibility-
weighted or quantitative susceptibility imaging may improve
sensitivity and accuracy for CMBs, separating haemorrhage
from mineralisation, but confirmatory neuropathological stud-
ies are warranted [91, 92].
Advanced Dynamic MRI Methods In Vivo in Rodents
and Humans
Cerebral Blood Flow and Cerebrovascular Reactivity
CVR refers to vasodilation and vasoconstriction of cerebral
microvessels, typically to vasoactive stimuli (e.g. increased
CO2 inspiration or intravenous acetazolamide). CVR is a
quintessential cerebrovascular health measure that reflects
the role of blood vessels in regulating CBF, oxygen and nu-
trient delivery, waste product clearance and dissipating heat
[93]. CBF is generally measured at rest, with ASL being a
widely used method [94].
Several studies have imaged CBF and CVR in SHR and
Wistar Kyoto (WKY) rats [55, 95]. However, anaesthetic
agents can affect resting CBF and haemodynamic responses
and therefore are particularly important to consider when plan-
ning experiments on CBF or CVR. For example, CBF was
higher in SHR versus in WKY under 2% isoflurane but not
with alpha-chloralose and isoflurane reduced CVR [96]. As in
preclinical functional neuroimaging, sedation rather than full
anaesthesia is often preferred [46]. Dexmedetomidine de-
presses global CBF; therefore, in some experiments, general
anaesthesia with inhalational agents may be preferable.
Anaesthetic protocols should also minimise impact on signal
and derived imaging variables; further optimisation studies and
standardised reporting of anaesthetic protocols would be
beneficial.
CVR requires a physiological manipulation/challenge but
voluntary breath holding is unsuited to preclinical studies [97]
and controlled hypercapnia via breathing apparatus is
more reliable. In rats and larger murine models, intuba-
tion provides greatest control of inhaled and exhaled
gases and is optimal for preclinical CVR. Sealed cham-
bers are practical where intubation is unviable or lower
level sedation is preferred. Since CO2 tolerance varies
between species [98, 99], tolerability should be balanced
against inducing robust signal changes. Humans tolerate
a 6% CO2 stimulus well [99].
CVR analyses typically use regression models but must
account for physiological and practical factors, notably
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haemodynamic delays, and filtering band frequency may vary
under anaesthesia [46].
CVR has not been fully exploited in rodents to better un-
derstand how impaired vasoreactivity develops at whole brain
level and leads to brain damage in SVD. Longitudinal CVR
measurements coupled with multiphoton microscopy via cra-
nial windows or isolated vessel preparations [100] could
strengthen the direct validation of in vivo CVR and improve
its use as a biomarker and an intermediary outcome in trials of
therapeutic interventions.
Blood–Brain Barrier Impairment
The BBB plays a central role in brain homeostasis, controlling
exchange of fluids and selected molecules while
protecting parenchyma from potentially toxic plasma
components [101]. BBB breakdown occurs in neurode-
generative diseases, including Alzheimer’s, Huntington’s
and SVD [102–107].
MRI, contrast-enhanced CT (CE-CT), PET and biofluid
biomarker approaches can measure BBB permeability [4].
MRI methods include dynamic or static contrast-enhanced
MRI [4, 11] and non-contrast-based methods (e.g. ASL
[108, 109] and T1-w black-blood imaging [110]). The most
widely used method to detect subtle focal BBB permeability
increases is DCE-MRI [102]. Preclinical validation is limited,
but in vivo BBB measures would complement histologic as-
sessment and validation of BBB dysfunction.
DCE-MRI involves T1-mapping followed by intravenous
Gd injection and repeated T1-w sequences [111]. Multi-slice
or volume sequences, usually GRE or fast low-angle shot, run
repeatedly for ca. 20 min; longer acquisitions may be appro-
priate for low-level leakage [112, 113]. Sequence optimisation
balances coverage, SNR and spatial and temporal resolution.
As pharmacokinetic analysis requires reliable arterial or ve-
nous input functions, identifiable vessels must be covered, e.g.
internal carotid arteries or sagittal sinus. High temporal reso-
lution is critical for bolus injections due to rapid blood signal
changes [113, 114]. A dilute contrast phantom adjacent to the
animal’s head can allow signal-to-concentration transforma-
tion correction. Anaesthesia level, temperature and respiration
should be monitored and adjusted to minimise input function
variation.
BBB function parameters, such as volume transfer con-
stants between extracellular space and plasma, are derived
by modelling the Gd concentration-time curve, along with
CBF and cerebral blood volume. There is now dedicated soft-
ware for clinical and preclinical DCE analyses (e.g.
ROCKETSHIP [115]). Patlak models are best suited to subtle
BBB leakage in SVD [112, 113]. Retinal imaging, MR ve-
nography [116] and phase contrast MRI [117] have been used
as surrogates to direct measurement of vessel diameter in re-
sponse to stimuli; further studies, particularly in humans at
field strengths ≥ 7 T, may provide more detailed insight into
properties of the microvasculature. Preclinically, methods like
multiphoton microscopy can also complement DCE-MRI by
determining the microvascular changes underpinning BBB
leakage [118].
There are novel MRI methods in development that use
endogenous contrast which may improve sensitivity. For ex-
ample, DW-pCASL employs diffusion weighting to distin-
guish labelled blood in the microvasculature from that
in brain tissue to measure water exchange [108].
WEPCAST also employs an ASL approach using veloc-
ity encoding to isolate venous signal [109]. However,
these approaches are hypothesis-based and their transla-
tion to humans would be greatly facilitated by first
demonstrating that they provide reliable measures of
BBB function in preclinical models.
MR Spectroscopy to Assess Metabolites
Magnetic resonance spectroscopy (MRS) determines tissue
metabolite levels in vivo and would provide a promising ap-
proach to explore SVD and neurodegenerative disease pro-
gression [14, 119–122]. However, MRS has not been applied
extensively in human SVD or preclinical models.
There are some practical limitations. For example, for sam-
pling homogeneous tissue, single voxel spectroscopy (SVS)
in mice requires typical volumes ca. 0.008 cm3 [123] (0.4% of
brain volume) relative to 4 cm3 (0.03%) in humans [124] and
positioning the sample volume requires structural imaging.
Multi-voxel MR spectroscopic imaging (MRSI) [125] in-
creases brain coverage and can examine metabolite distribu-
tion, although with longer acquisition times. It is impor-
tant to control for disease burden and relative propor-
tions of healthy/diseased tissue, particularly in advanced
disease, and where atrophy reduces the amount of tissue
to sample. It is important to establish the test-retest
reliability on individual MRI scanners, particularly for
lactate and coupled metabolites [126] before use in ex-
periments although the reproducibility for detecting
more abundant metabolites is generally good and sever-
al quantification approaches are available [124].
Surface and/or refined coil designs improve rodent MRS
sensitivity [127] and higher field strengths provide better
spectral resolution and distinction of metabolite peaks.
Preclinical MRS allows cross-validation of metabolite con-
centrations using chemical methods, providing greater confi-
dence scanning humans longitudinally.
Beyond proton MRS, carbon-13, oxygen-17, sodium-23
and phosphorus-31 MRS may be applied, though multi-
nuclear equipment is needed. Contrast agents, notably deute-
rium [128] and thulium [129], can monitor metabolism, pH
and temperature in vivo to assess disease progression or
changes in ketogenic states.
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Novel MRI Methods in Rodents and Scope for Rodent-Human
Translation
PVS are small conduits that envelop penetrating cerebral
arterioles/venules where CSF can exchange with interstitial
fluid (ISF) [48]. As part of the glymphatic system, PVS are
thought to clear brain fluid and waste, facilitated by
aquaporin-4 (AQP4) water channel–mediated CSF-ISF ex-
change at the peri-capillary space before clearance to lymphat-
ic vessels [34, 130, 131]. While aspects of the physiology are
controversial [132, 133], CSF-ISF exchange studies provide
opportunities to understand PVS in vascular and neurodegen-
erative diseases. PVS become enlarged and more visible in
SVD and are associated with inflammation, impaired CVR,
increased BBB permeability and vascular pulsatility [48].
Their small size makes them difficult to assess in humans.
However, CSF delivery to PVS can be characterised in ro-
dents using DCE-MRI and Gd injection into the cisterna
magna CSF. Small volume infusion of Gd into the CSF pool
during 3D MRI demonstrates spatially and temporally re-
solved solute transport through the brain [134] and can show
altered PVS function with vascular risk factors. For example,
type 2 diabetes mellitus rats exhibit slower Gd clearance, with
accumulation and retention, enhanced perivascular arterial in-
flux and increased hippocampal signal intensity [39]. Tracer
transport mechanisms are highly complex, but pharmacoki-
netic models [135, 136] and mass transport algorithms [137,
138] help quantify influx/efflux contributions. An optimal
mass transport analysis in SHRSP rats reveals reduced and
slowed solute transport from CSF into the brain [139].
Though rare, opportunistic human studies show CSF solute
transport into basal brain parenchyma over longer times with
similar distributions [140–142].
Gd injection into the cisterna magna in humans is not a
practical technique; Gd injections into the lumbar CSF and
tracking through the intracranial CSF have been done rarely
and only when diagnosing pathological conditions. More clin-
ically applicable although less sensitive techniques to track
PVS function include diffusion imaging, PC-MRI and ultra-
fast MR imaging. In rodents, T2-w diffusion techniques
showed CSF in PVS preferentially moved parallel to blood
flow fluctuating with cardiac pulsation, consistent with PVS-
CSFmovement [143] but has yet to be applied in humans. PC-
MRI shows that intracranial arterial, venous and CSF
pulsatility in the main cisterns, correlate with WMH burden
in SVD [144–146], depends on directional flow and is less
suited to understanding water mobility within the brain.
Magnetic resonance encephalography (MREG) is an emerg-
ing high temporal resolution sequence, which is thought to
reveal spatial-temporal patterns driven by different cardiac,
respiratory and vasomotor forces highlighting that cerebral
water movement is directional and cyclic with several drivers
[147]. Recent work with APQ4-deficient mice suggests multi-
echo ASL may provide insight into clearance mechanisms
[148]. Such methods may reveal new insights into SVD, par-
ticularly large calibre vessel pulsatility effects on spatiotem-
poral water movement characteristics, although preclinical
validation remains key.
Discussion
Major advances have occurred in understanding human SVD,
thanks to modern MRI methods; however, large gaps in
knowledge remain which could be addressed through a range
of SVD models and capitalising on multiple forms of clinical-
ly relevant image contrasts available with MRI. We demon-
strate the need for greater transferability and reproducibility of
preclinical-clinical MRI findings. There are numerous rele-
vant rodent models for SVD. However, as yet, the imaging
approaches do not appear to be taking full advantage of the
knowledge derived from characterising human disease and
thus limit the translational potential of rodent models in
SVD. Further studies to ascertain key features of SVD and
disease progression would help focus preclinical rodent
models on the most salient features, whether structural or dy-
namic measures (e.g. WMH and PVS burden, cerebrovascular
reactivity, BBB leakage etc). Many of the imaging techniques
commonly used clinically have already been applied to vari-
ous rodent models, including structural MR and techniques to
investigate BBB integrity. However, several structural se-
quences are necessary in human MRI to capture the features
properly and this approach could improve the yield of preclin-
ical MRI. Closer matching of clinical to preclinical imaging
protocols may aid comparisons of data and provide a fuller
picture of differences in SVD disease progression and
manifestations.
Only limited use has been made of ex vivo MRI and his-
tology in studying SVD to date, though potentially relevant
protocols exist for several relevant features. Greater use of
these techniques may help determine which cellular mecha-
nisms are at work, while improving understanding of the gen-
esis and evolution of lesions and other imaging features, such
as WMH and CMBs. Availability of human tissue, particular-
ly from intermediate disease states, remains an obstacle; how-
ever, many questions can be explored with greater use of
animal histology, in vivo and PM-MRI.
For dynamic imaging methods in rodents, determining the
optimal anaesthetic regimen and the effect on derived imaging
metrics is a significant challenge, but would help improve
comparability between preclinical and hence clinical studies.
Rodent models allow direct in vivo validation which would
significantly advance understanding of underlying disease
mechanisms, and emerging imaging methods, including syn-
theticMRI [149], with the potential to quantify disease-related
tissue properties in vivo. Using comparable processing and
Transl. Stroke Res.
analysis methods in preclinical and clinical imagingwill great-
ly increase translational potential [113]. Application of similar
image analysis methods to animal and human studies is en-
tirely feasible, would avoid repeating the same errors, improve
translation and is encouraged [22, 54, 115].
Preclinical models have also enabled advances in under-
standing of microvascular dysfunction underlying SVD and
methods to measure paravascular transport. While the initial
approaches, based on relatively invasive techniques, are not
applicable in routine clinical studies, it has stimulated interest
in alternative imaging methods for humans which show some
promise.
Imaging of SVD is key to advancing understanding
of disease pathophysiology and aiding the development
of novel treatments. There is immense untapped poten-
tial for clinical research to inform preclinical work and
vice versa. To maximise the benefits of research into
SVD, there is a need for greater engagement and active
collaborations between clinical and preclinical re-
searchers to develop research programmes taking full
account of the latest advances in both domains.
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